Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06233110

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

Chronic Graft Versus Host Disease Clinical Trial

Official title:
Phase I Trial of Ruxolitinib Plus Fostamatinib for the Treatment of Steroid Refractory Chronic Graft Versus Host Disease

Clinical Trial Summary

This is an open-label phase I study of fostamatinib in combination with ruxolitinib for the treatment of chronic GvHD with a suboptimal response to corticosteroids. The primary objective is to identify a minimum safe and biologically effective dose of fostamatinib when combined with standard of care ruxolitinib for the treatment of steroid refractory and steroid dependent cGVHD. The secondary objective is to estimate the efficacy of the combination of ruxolitinib and fostamatinib for the treatment of steroid refractory and steroid dependent cGVHD. The target enrollment is 24-30 subjects. The study will begin with an initial dose escalation cohort employing a modified 3+3 design to investigate up to three doses of fostamatinib. Using safety, efficacy, pharmacodynamic (PD), and pharmacokinetic data (PK), an interim assessment will be performed to determine two candidate doses of the biologically optimal dose to investigate further. A safety expansion cohort will be opened to backfill these two candidate doses up to a total 12 patients per dose, including those in the dose escalation cohort who received the candidate doses. Patients will then be randomized to one of these two candidate doses in te expansion. A final analysis of safety, efficacy, and PK/PD data in patients who received the two candidate doses will be conducted to determine a minimum safety and biologically effective dose, which will be the recommended phase II dose (RP2D). The primary hypothesis is that Fostamatinib combined with ruxolitinib is a safe therapy for and has synergistic activity in cGvHD. The recommended phase II dose will be determined by the study investigators in collaboration with the sponsors. The decision to select the recommended phase II dose will occur only after all patients in the part 1 have completed at least 28 days of therapy. The decision will be based on the valuation of all relevant, available data, and not solely on dose-limiting toxicities.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06233110
Study type Interventional
Source Duke University
Contact Chenyu Lin, MD
Phone 919-684-8964
Email chenyu.lin@duke.edu
Status Not yet recruiting
Phase Phase 1
Start date September 1, 2024
Completion date July 1, 2029
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Terminated NCT02337517 - Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT02461134 - Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD Phase 2
Recruiting NCT03839069 - Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis N/A
Active, not recruiting NCT00637689 - Improving Outcomes Assessment in Chronic GVHD
Active, not recruiting NCT01937468 - Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Phase 1
Completed NCT01380535 - Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) Early Phase 1
Completed NCT01810718 - Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD Phase 1
Terminated NCT01964625 - Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD) N/A
Active, not recruiting NCT03790332 - Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) Phase 1/Phase 2
Completed NCT01680965 - Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Phase 1/Phase 2
Completed NCT02491359 - Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease Phase 2
Recruiting NCT06300320 - A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease Phase 2
Recruiting NCT05922761 - BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Phase 2
Terminated NCT02701634 - Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD) Phase 2
Recruiting NCT06247150 - Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD) N/A
Active, not recruiting NCT04212416 - Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease Phase 1
Completed NCT02959944 - Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) Phase 3
Completed NCT01954979 - Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) Phase 1
Active, not recruiting NCT04640025 - A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib Phase 2